Premium
Influence of the blood‐ CSF ‐barrier function on S100B in neurodegenerative diseases
Author(s) -
Steinacker P.,
Weidehaas K.,
Cepek L.,
Feneberg E.,
Kretzschmar H. A.,
Otto M.
Publication year - 2013
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12113
Subject(s) - biomarker , albumin , medicine , cerebrospinal fluid , pathology , serum albumin , blood–brain barrier , central nervous system , biology , biochemistry
Objectives S100B was proposed to be a CSF and blood biomarker in a number of neurological diseases. The route of S100B to the CSF and the blood in neurodegenerative diseases is unclear. To assess the impact of the physiological or impaired blood‐ CSF ‐barrier ( BCSFB ) function on S100B concentrations in CSF and serum, we analysed S100B in correlation of the albumin quotient. Materials and methods S100B serum and S100 B CSF were quantified in samples from patients with a variety of neurological diseases using an immunoluminometric assay (Sangtec LIA ‐mat). Measures were analysed for a potential relation to the CSF /serum‐albumin quotient ( Q alb ), which indicates the BCSFB functionality. Results We reasserted increased S100B concentrations in CSF and serum of CJD patients. Elevated S100B serum correlated with elevated S100 B CSF in all diagnoses but with exceptions. Neither S100 B CSF nor S100B serum did correlate with Q alb , even when the BCSFB function was progressively impaired as demonstrated by increased Q alb . Conclusions The lack of correlation between Q alb and S100 B CSF is typically seen for proteins which are brain derived. Therefore, we propose that S100B enters the blood with the bulk flow via Pacchioni's granules and along the spinal nerve sheaths.